PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature

Research output: Contribution to journal › Review › Research › peer-review

Standard

PET tracers for somatostatin receptor imaging of neuroendocrine tumors : current status and review of the literature. / Johnbeck, Camilla Bardram; Knigge, Ulrich; Kjær, Andreas.

In: Future Oncology, Vol. 10, No. 14, 11.2014, p. 2259-2277.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Johnbeck, CB, Knigge, U & Kjær, A 2014, 'PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature', Future Oncology, vol. 10, no. 14, pp. 2259-2277. https://doi.org/10.2217/fon.14.139

APA

Johnbeck, C. B., Knigge, U., & Kjær, A. (2014). PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncology, 10(14), 2259-2277. https://doi.org/10.2217/fon.14.139

Vancouver

Johnbeck CB, Knigge U, Kjær A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncology. 2014 Nov;10(14):2259-2277. https://doi.org/10.2217/fon.14.139

Author

Johnbeck, Camilla Bardram ; Knigge, Ulrich ; Kjær, Andreas. / PET tracers for somatostatin receptor imaging of neuroendocrine tumors : current status and review of the literature. In: Future Oncology. 2014 ; Vol. 10, No. 14. pp. 2259-2277.

Bibtex

@article{82700322765441d988bd39ed706bc083,
title = "PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature",
abstract = "Neuroendocrine tumors have shown rising incidence mainly due to higher clinical awareness and better diagnostic tools over the last 30 years. Functional imaging of neuroendocrine tumors with PET tracers is an evolving field that is continuously refining the affinity of new tracers in the search for the perfect neuroendocrine tumor imaging tracer. (68)Ga-labeled tracers coupled to synthetic somatostatin analogs with differences in affinity for the five somatostatin receptor subtypes are now widely applied in Europe. Comparison of sensitivity between the most used tracers - (68)Ga-DOTA-Tyr3-octreotide, (68)Ga-DOTA-Tyr3-octreotate and (68)Ga-DOTA-l-Nal3-octreotide - shows little difference and expertise on the specific tracer used, and knowledge regarding physiological uptake might be more important than in vitro-proven differences in affinity. Using isotopes such as (18)F or (64)Cu might improve these PET tracers further.",
author = "Johnbeck, {Camilla Bardram} and Ulrich Knigge and Andreas Kj{\ae}r",
year = "2014",
month = nov,
doi = "10.2217/fon.14.139",
language = "English",
volume = "10",
pages = "2259--2277",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "14",

}

RIS

TY - JOUR

T1 - PET tracers for somatostatin receptor imaging of neuroendocrine tumors

T2 - current status and review of the literature

AU - Johnbeck, Camilla Bardram

AU - Knigge, Ulrich

AU - Kjær, Andreas

PY - 2014/11

Y1 - 2014/11

N2 - Neuroendocrine tumors have shown rising incidence mainly due to higher clinical awareness and better diagnostic tools over the last 30 years. Functional imaging of neuroendocrine tumors with PET tracers is an evolving field that is continuously refining the affinity of new tracers in the search for the perfect neuroendocrine tumor imaging tracer. (68)Ga-labeled tracers coupled to synthetic somatostatin analogs with differences in affinity for the five somatostatin receptor subtypes are now widely applied in Europe. Comparison of sensitivity between the most used tracers - (68)Ga-DOTA-Tyr3-octreotide, (68)Ga-DOTA-Tyr3-octreotate and (68)Ga-DOTA-l-Nal3-octreotide - shows little difference and expertise on the specific tracer used, and knowledge regarding physiological uptake might be more important than in vitro-proven differences in affinity. Using isotopes such as (18)F or (64)Cu might improve these PET tracers further.

AB - Neuroendocrine tumors have shown rising incidence mainly due to higher clinical awareness and better diagnostic tools over the last 30 years. Functional imaging of neuroendocrine tumors with PET tracers is an evolving field that is continuously refining the affinity of new tracers in the search for the perfect neuroendocrine tumor imaging tracer. (68)Ga-labeled tracers coupled to synthetic somatostatin analogs with differences in affinity for the five somatostatin receptor subtypes are now widely applied in Europe. Comparison of sensitivity between the most used tracers - (68)Ga-DOTA-Tyr3-octreotide, (68)Ga-DOTA-Tyr3-octreotate and (68)Ga-DOTA-l-Nal3-octreotide - shows little difference and expertise on the specific tracer used, and knowledge regarding physiological uptake might be more important than in vitro-proven differences in affinity. Using isotopes such as (18)F or (64)Cu might improve these PET tracers further.

U2 - 10.2217/fon.14.139

DO - 10.2217/fon.14.139

M3 - Review

C2 - 25471038

VL - 10

SP - 2259

EP - 2277

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 14

ER -

ID: 137324436